An open, randomised, parallel-group phase III study to compare ZOLADEX 3.6 mg monotherapy with ZOLADEX 3.6 mg + tamoxifen or tamoxifen monotherapy in premenopausal Japanese women with oestrogen-positive breast cancer who had undergone curative resection

Study identifier:ZXBC-1002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open, randomised, parallel-group phase III study to compare ZOLADEX 3.6 mg monotherapy with ZOLADEX 3.6 mg + tamoxifen or tamoxifen monotherapy in premenopausal Japanese women with oestrogen-positive breast cancer who had undergone curative resection

Medical condition

Breast Cancer

Phase

N/A

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

-

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria